EVENGI Platform
EVENGI harnesses both sEV bioengineering and sEV bioproduction to develop new generations of therapeutics and preventive solutions to improve patients' lives.
Ciloa is an all-in-one R&D and biomanufacturing powerhouse, with complete sEV expertise based on over 24 years of experience. Our technology, R&D, know-how and cleanroom facilities have enabled us to create EVENGI a unique bioengineering and manufacturing platform for robust and reliable bioengineered sEV productions.
This is evident in our pipeline of over 130 bioengineered small extracellular vesicles (sEVs) that are leading candidates for therapeutic and preventive applications. The company has a partnered development offering for new medical solutions.
The challenges of sEV bioproduction overcome
In addition to bioengineering sEVs, the challenge of obtaining stable sEVs through a robust and reliable production process is well recognized.
With 24 years of experience, Ciloa has developed a fully integrated production, purification, and qualification process that has produced dozens of stable, homogeneous sEV batches from hundreds of liters of culture medium.
The production process is so high-performing that it enables Ciloa to deliver small bioengineered extracellular vesicles (sEVs) that are stored in a simple saline buffer. These sEVs are stable at 4°C for several months or even years (up to 2.5 years for sEVs carrying a G protein-coupled receptor (GPCR)).
A wide range of applications
The EVENGI platform’s ability to produce stable batches of bioengineered sEVs enables the development of disruptive therapeutic solutions (APN-EV) and vaccines against metabolic diseases and viral pandemics. The platform also enables the establishment of research partnerships to address your medical challenges.